Influenza A Virus H7N9 Infection Drug Pipeline Study, H2 2018 - Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs

Dublin, Feb. 26, 2019 (GLOBE NEWSWIRE) -- The "Influenza A Virus H7N9 Infection Drug Pipeline Study, H2 2018- Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs for Influenza A Virus H7N9" report has been added to ResearchAndMarkets.com's offering.

Influenza A Virus H7N9 infection is spread through Clostridium tetani bacteria, which is present in the form of spores in the environment and develops as bacteria upon entering into human body. Painful muscle contractions are the primary symptom and the disease is also referred to as lockjaw' as jaw muscles are tightened in tetanus infected patient.

Different forms of tetanus include- general, local and cephalic tetanus. Sudden spasms of the vocal cords, fractures, infections, aspiration pneumonia are the major complications of the disease.

Despite low costs of treatment, tetanus is rapidly progressing infectious disease, causing mortality. Fourteen companies are currently developing vaccines and treatment options against tetanus infections. The companies in global tetanus pipeline include- Beijing Minhai Biotechnology Co Ltd, BIKEN Corporation, Biological E Ltd, Cadila Healthcare Ltd, Daiichi Sankyo Company, GC Pharma- Korea, GlaxoSmithKline Plc, Indian Immunologicals Ltd, LG Chem Ltd, Olymvax Biopharmaceuticals Inc, Panacea Biotec Ltd, Sanofi, Serum Institute of India Ltd and Wockhardt Ltd.

Report Description:

The Influenza A Virus H7N9 Infection pipeline guide presents complete overview of drugs currently being developed for Influenza A Virus H7N9 Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Influenza A Virus H7N9 Infection pipeline candidate.
Research and Development progress along with latest news related to each of the Influenza A Virus H7N9 Infection pipeline candidates is included.

Major companies participating in therapeutic development of Influenza A Virus H7N9 Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Influenza A Virus H7N9 Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Influenza A Virus H7N9 Infection clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Influenza A Virus H7N9 Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

Scope of Influenza A Virus H7N9 Infection pipeline report includes:

• Panorama of Influenza A Virus H7N9 Infection pipeline markets including statistics on therapeutic drugs and companies involved
• Influenza A Virus H7N9 Infection Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
• Influenza A Virus H7N9 Infection pipeline candidates across various Mechanism of Actions' are also presented in the study
• Overview of companies participating in Influenza A Virus H7N9 Infection pipeline with short introduction to their businesses and pipeline projects
• For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
• Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Influenza A Virus H7N9 Infection pipeline therapeutics

Reasons to Buy:

• Get clear understanding of the entire Influenza A Virus H7N9 Infection pipeline, with details on active projects
• Get in detail information of each product with updated information on each project along with key milestones
• Know the list of companies participating in global Influenza A Virus H7N9 Infection pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

Key Topics Covered:

I. Key Findings

1. Companies Investing in Influenza A Virus H7N9 Infection Pipeline include-
Number of Companies with Influenza A Virus H7N9 Infection projects in pre-clinical Development-
Number of Companies with Influenza A Virus H7N9 Infection projects in Clinical Development-
Influenza A Virus H7N9 Infection Pipeline Companies based in Americas
Influenza A Virus H7N9 Infection Pipeline Companies based in Europe
Influenza A Virus H7N9 Infection Pipeline Companies based in Asia Pacific
Influenza A Virus H7N9 Infection Pipeline Companies based in Rest of the World

2. Pipeline Candidates include-
Influenza A Virus H7N9 Infection Pipeline Agents in pre- clinical/ Discovery stage of Development
Influenza A Virus H7N9 Infection Pipeline Agents in Clinical Development stage
Influenza A Virus H7N9 Infection Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Influenza A Virus H7N9 Infection Pipeline agents

II. Insights into Influenza A Virus H7N9 Infection Pipeline -

1. Disease Overview
Introduction to Influenza A Virus H7N9 Infection
Symptoms and Causes of Influenza A Virus H7N9 Infection
Treatment or Prevention Options for Influenza A Virus H7N9 Infection
Other Details
2. Phase wise Pipeline Compounds
Influenza A Virus H7N9 Infection Pipeline- Pre- Clinical/ Discovery stage Drugs
Influenza A Virus H7N9 Infection Pipeline- Phase 1 stage Drugs
Influenza A Virus H7N9 Infection Pipeline- Phase 2 stage Drugs
Influenza A Virus H7N9 Infection Pipeline- Phase 3 stage Drugs
Influenza A Virus H7N9 Infection Pipeline- Pre-Registration stage Drugs
3. Company wise Influenza A Virus H7N9 Infection Pipeline Compounds
4. Influenza A Virus H7N9 Infection Pipeline by Mechanism of Action

III. Influenza A Virus H7N9 Infection Pipeline Compound Details

• MD 2009
• CC-42344
• CDX-H7N9
• Influenza A virus H7N9 vaccine
• haemagglutinin inhibitor
• H7N9 avian influenza vaccine
• Influenza A (H7N9) virus vaccine
• MT-7529
• AT-501
• mRNA-1851
• NV-INF-1
• NV-INF-2
• Influenza A virus H7N9 vaccines (Pandemic)
• AS03
• H7N9 influenza vaccine
• Baloxavir marboxil
• VH244
• VIS410
• VB126 LAIV

Drug Details

1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/ License Partner
Orphan Drug / Fast Track/ Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details

IV. Influenza A Virus H7N9 Infection Pipeline Company Briefs

• AusBio Ltd
• Cocrystal Pharma Inc
• Codagenix
• EpiVax
• Genentech Inc
• Greffex Inc
• Hualan Biological Bacterin Co Ltd
• Medicago Inc
• Medigen Vaccine Biologics Corp
• Moderna Therapeutics Inc
• NanoViricides Inc
• NanoViricides Inc
• Protein Sciences Corporation
• sanofi pasteur
• Shanghai Institute of Biological Products
• Shionogi & Co Ltd
• VirionHealth Ltd
• Visterra Inc
• Vivaldi Biosciences Inc

V. Latest News and Developments in Global Influenza A Virus H7N9 Infection Pipeline Market

VI. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/65pgs9/influenza_a_virus?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Press Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    Related Topics: Infectious Diseases Drugs